OnCo
drugsProductWithdrawn

Tusamitamab ravtansine

Tusamitamab ravtansine was Sanofi's ADC against the classic CEA tumour marker, stopped for futility in lung cancer in 2023.

A CEACAM5-directed ADC with a DM4 maytansinoid payload. Phase 3 CARMEN-LC03 (vs docetaxel in CEACAM5-high non-squamous NSCLC) was stopped in December 2023 when an interim analysis showed the PFS endpoint would not be met; OS was not improved. Sanofi discontinued the whole programme.

Lesson: a tubulin-inhibitor payload at DAR ~4 with a non-permeable release mechanism could not match the TOP1-payload ADC bar set in lung cancer; CEACAM5 itself remains under study with T-cell engagers.

Loading structure…
|
Payload: DM4 (ravtansine) · 2D coordinates (no PubChem conformer)
PubChem
How it works, step by step · animated schematic, not to scale
Antibody-drug conjugate (ADC) →
Modality
ADC
Mechanism
Humanised anti-CEACAM5 IgG1 with DM4 via cleavable SPDB linker.
Brand / code
SAR408701
Payload
DM4 (ravtansine)
Linker
SPDB disulfide

Trials

top
ClinicalTrials.gov · phase 2/3
refreshed 2026-09-09
8 studies0 recruiting7 Phase 21 Phase 3
Search “Tusamitamab ravtansine” on ClinicalTrials.gov →
Counts are from a name search and may include unrelated studies; up to 100 studies are summarised.

Recruiting now (live from ClinicalTrials.gov)

Recruiting trials near you · live from ClinicalTrials.gov
Tusamitamab ravtansine
intervention: Tusamitamab ravtansine
Open on ClinicalTrials.gov →

Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.

Latest papers

top
Literature trend4 papers in the last 12 months-20% vs prior 12How this is computed
Latest papers · live from Europe PMC
Open in Europe PMC

Query for this drug: (TITLE:"Tusamitamab ravtansine" OR ABSTRACT:"Tusamitamab ravtansine" OR TITLE:"SAR408701" OR ABSTRACT:"SAR408701") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Tusamitamab ravtansine, not a curated reading list.

Connected

5top

Pages like this

not linked directly; found by shared links

cancers

1
Non-small-cell lung cancer

technologies

1
Antibody-drug conjugate (ADC)

targets

1
CEACAM5

companies

1
Sanofi

bottlenecks

1
Failures are hidden